The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

NCT07203729 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

184

Enrollment

OTHER

Sponsor class

Conditions

HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis

Interventions

DRUG: Trastuzumab Rezetecan
DRUG: Chemotherapy of Physician's Choice

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences